use of FDA oral polio formula in vaccinating Saudi children

To evaluate the immunogenicity of USA [FDA] Oral polio vaccine versus WHO Oral polio vaccine. Open randomized trial where 210 children were randomized into three groups. First group received Hemophilus influenza type b [Hib] vaccine plus WHO DTP and OPV. The second group received Hib plus FDA DTP and OPV. The third group received WHO DTP and OPV without Hib vaccine. 3 doses were given at 6 weeks, 3 months and 5 months. Blood samples were collected at 6 months of age. Bar coded sera were used to assess for polio antibody for the three poliovirus types using microneutralization assay. The result of polio assay will be presented in this paper. Proportion of children with detectable antibody [titre =/> 1/8] polioviruses were higher in the group vaccinated with the FDA OPV formula but no significant difference was found for our sample size. FDA oral polio is not superior to WHO OPV at our sample size and there is an improvement in the seroresponse to WHO OPV compared to previous survey

use of a modified out-patient infusion therapy for lowering the cost in suleimania child's hospital

The aim of this paper is to evaluate the cost-saving of outpatient parenteral antibiotic therapy for meningitis in Suleimania Children's Hospital in Riyadh measured as the number of hospital days saved. Twenty-one cases of meningitis treated with Ceftriaxone were included in a retrospective record analysis. Ceftriaxone was given for an average of 6 days as inpatient then for an average of 5 days on an outpatient basis. A significant statistical difference was found between the actual and expected length of stay if all the injection were given as inpatient [p < 0.0001]. A total of 109 days were saved by this system for meningitis only. More hospital days can be saved by including other diseases like enteric fever in this system. Important issues should be solved such as safety, patient selection and quality assurance before extending the implementation of this system